<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02418793</url>
  </required_header>
  <id_info>
    <org_study_id>CP-5-001</org_study_id>
    <nct_id>NCT02418793</nct_id>
  </id_info>
  <brief_title>A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B</brief_title>
  <official_title>A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Opko Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Opko Biologics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the current Phase 1/2a single dose, dose-escalating study is to evaluate the
      acute safety, pharmacokinetics (PK) and pharmacodynamics (PD) properties of MOD-5014 in adult
      subjects with moderate/severe congenital hemophilia A or B. This will be a single-dose, open
      label, dose-escalating study. Each dose cohort will be concluded by a safety review,
      following which escalation to the next dose cohort will be approved.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite safety and tolerability parameters as measured by adverse events, electrocardiograms (ECG), laboratory results, vital signs and injection site reactions</measure>
    <time_frame>30 days</time_frame>
    <description>To assess the acute safety and tolerability of single intravenous (IV) administration of escalating MOD-5014 doses in hemophilic subjects with and without inhibitors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile</measure>
    <time_frame>14 days</time_frame>
    <description>To evaluate the pharmacokinetic profile (MOD-5014 serum levels; Area Under the Curve (AUC); Cmax; Tmax; T1/2) of single IV administration of escalating MOD-5014 doses in hemophilic subjects with and without inhibitors.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamic Profile (evaluate the pharmacodynamic response (FVIIa clotting activity, coagulation parameters) of single IV administration of escalating MOD-5014 doses)</measure>
    <time_frame>14 days</time_frame>
    <description>To evaluate the pharmacodynamic response (FVIIa clotting activity, coagulation parameters) of single IV administration of escalating MOD-5014 doses in hemophilic subjects with and without inhibitors.</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hemophilia A</condition>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>Dose Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lowest MOD-5014 dose tested in the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOD-5014 Dose cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOD-5014 Dose cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOD-5014 Dose cohort 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MOD-5014 Dose cohort 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Highest MOD-5014 dose tested in the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOD-5014</intervention_name>
    <description>Long Acting Factor VIIa</description>
    <arm_group_label>Dose Cohort 1</arm_group_label>
    <arm_group_label>Dose Cohort 2</arm_group_label>
    <arm_group_label>Dose Cohort 3</arm_group_label>
    <arm_group_label>Dose Cohort 4</arm_group_label>
    <arm_group_label>Dose Cohort 5</arm_group_label>
    <arm_group_label>Dose Cohort 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of moderate or severe congenital Hemophilia A or B with or without
             inhibitors

        Exclusion Criteria:

          -  Diagnosis of any coagulation disorder other than Hemophilia A or B

          -  Receipt of any immunomodulatory therapy within 3 months prior to screening, with the
             exception of Hepatitis C or HIV therapy

          -  Have had, within one month prior to study drug administration, a major surgical
             procedure (e.g. orthopedic, abdominal) or have an elective surgery planned within the
             study period

          -  Use of any anticoagulant for arterial/venous obstructions and/or atrial fibrillation
             within 7 days prior to first study drug administration

          -  Malignancy within past 5 years (excluding non-melanoma skin cancer)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Ben-Bashat</last_name>
    <role>Study Director</role>
    <affiliation>Opko Biologics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ingrid Mintautas</last_name>
    <phone>1-630 460-0026</phone>
    <email>imintautas@opko.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lior Binder</last_name>
    <phone>972-54-805-4899</phone>
    <email>lbinder@opko.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Mintautas</last_name>
    </contact>
    <investigator>
      <last_name>Nadia Ewing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Mintautas</last_name>
      <phone>630-460-0026</phone>
      <email>imintautas@opko.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orthopaedic Hemophilia Treatment Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Mintautas</last_name>
    </contact>
    <investigator>
      <last_name>Doris Quon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Mintautas</last_name>
    </contact>
    <investigator>
      <last_name>Jonathan Ducore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Mintautas</last_name>
    </contact>
    <investigator>
      <last_name>Lisa Boggio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bleeding &amp; Clotting Disorders Institute</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Mintautas</last_name>
    </contact>
    <investigator>
      <last_name>Michael Tarantino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Hemophilia &amp; Thrombosis Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Mintautas</last_name>
    </contact>
    <investigator>
      <last_name>Amy Shapiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Mintautas</last_name>
    </contact>
    <investigator>
      <last_name>Elaine Eyster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian Shadyside</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Mintautas</last_name>
    </contact>
    <investigator>
      <last_name>Margaret Ragni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Mintautas</last_name>
    </contact>
    <investigator>
      <last_name>Yu-Min Shen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Gulf States Hemophilia and Thrombophilia Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Mintautas</last_name>
    </contact>
    <investigator>
      <last_name>Miguel Escobar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2015</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemophilia</keyword>
  <keyword>Factor VII</keyword>
  <keyword>Factor VIIa</keyword>
  <keyword>Inhibitors</keyword>
  <keyword>Long Acting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

